Partnership includes six Scripps Labs, which will each receive funds to expand basic research capacity.
Sigma-Aldrich will fund research and also share its research on the synthesis and analysis of potential drugs with The Scripps Institute. This is believed to be the first formal partnership between a research institute and a reagents company.
The Scripps Institute has recently entered into additional corporate agreements with Bristol-Myers Squibb and Janssen Pharmaceuticals.
Eric Green, Executive Vice President and President, Research at Sigma-Aldrich, notes in the release, “We believe this partnership reinforces our strategy of broadening our research portfolio of innovative products and tools used by the translational research community.”
Subscribe to our mailing list, and we'll keep you posted of the latest developments.